20-F: Holdco Nuvo Group D.G Ltd. Files 2023 Annual Report on Form 20-F

Holdco Nuvo Group D.G Ltd. releases its 2023 annual report, detailing financial performance and key business activities.

Summary

• Holdco Nuvo Group D.G Ltd. has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023.
• The report details the company's business, financial condition, and operating results.
• The company is focused on commercializing its INVU platform for remote fetal monitoring.
• The audited consolidated financial statements for the year ended December 31, 2023, include an explanatory paragraph in our independent registered public accounting firms audit report stating that there are conditions that raise substantial doubt about our ability to continue as a going concern.
• The company will need to obtain additional financing to fund its future operations and continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as commercial contracts and a strategic partnership, the company's financial situation raises concerns about its ability to continue as a going concern. The need for additional financing and the competitive landscape add further uncertainty.

Positives

• The company has signed over a dozen commercial contracts with health systems, large private practice groups, and independent women's health practices in the United States and Israel.
• The company has a strategic partnership with Philips primarily focused on providing a jointly integrated remote fetal monitoring solution targeted toward hospital networks in the U.S.
• The company has an extensive global patent portfolio consisting of 16 issued U.S. patents, 10 pending U.S. utility patent applications, 43 issued foreign utility patents, one allowed foreign utility patent application, 13 pending foreign utility patent applications and one PCT patent application.

Negatives

• The audited consolidated financial statements for the year ended December 31, 2023, include an explanatory paragraph in our independent registered public accounting firms audit report stating that there are conditions that raise substantial doubt about our ability to continue as a going concern.
• The company will need to obtain additional financing to fund its future operations and continue as a going concern.
• The company has a limited operating history and only a preliminary and unproven business plan.
• The company has a history of net losses, and expects to continue to incur losses for the foreseeable future.

Risks

• Nuvo is a development-stage company with a limited operating history, and may never be able to effectuate its business plan, achieve meaningful revenue or attain profitability.
• Nuvo is highly dependent on the successful development, marketing and sale of the INVU platform and the related products and services.
• Nuvo will need to obtain additional financing to fund its future operations and continue as a going concern.
• The manufacturing and supply of the INVU platform is subject to various factors outside Nuvos direct control, including those related to Nuvos dependence on third-party manufacturers and suppliers.
• Nuvos medical device operations are subject to pervasive and continuing FDA regulatory requirements, and failure to comply with these requirements could harm its business, financial condition and results of operations.
• Conditions in Israel could materially and adversely affect Nuvos business.
• Holdco will incur increased costs as a result of operating as a public company.
• A market for Holdco Ordinary Shares may not develop, which would adversely affect the liquidity and price of Holdco Ordinary Shares.
• The price of Holdco Ordinary Shares may be volatile.

Future Outlook

The company expects to continue to incur operating losses in the near term and will need additional funding to meet operational needs and capital requirements.

Industry Context

The pregnancy monitoring and management industry is rapidly evolving and subject to intense and increasing competition. The company aims to disrupt the market with its INVU platform, offering a more convenient and data-driven approach to pregnancy care.

Comparison to Industry Standards

• The INVU platform competes with existing monitoring devices such as Monica Healthcare (now part of General Electric), Nemo Healthcare, and Philips Avalon CL, which are limited to use within healthcare facilities.
• The INVU platform also competes with devices that seek to provide distributed care, such as Sense4Baby, Pregnabit, Bloom, and Heramed.
• The company believes its INVU platform is the only system that tackles both data quality and distributed care by ensuring a comfortable shift of care to a remote setting while providing high-fidelity digital data.

Management Changes

Related Party Transactions

• Certain of the Interim Financing Investors are affiliated with LAMF and the Sponsor and invested an aggregate of $2,000,000 in the Interim Financing.
• Gaingels 10x Capital Diversity Fund I, LP is a Bridge Financing Holder, holding an aggregate principal amount of $1.0 million of Bridge Financing Notes and related warrants to purchase 273,647 Holdco Ordinary Shares, is an affiliate of a member of the Sponsor and serves as collateral agent with respect to the collateral securing the Bridge Financing Notes.
• Gerald Ostrov, a member of the Holdco Board, holds an aggregate principal amount of $636,000 of Bridge Financing Notes and related warrants to purchase 174,039 Holdco Ordinary Shares.
• Robert Powell, our Chief Executive Officer and a member of the Holdco Board, holds an aggregate principal amount of $100,000 of Bridge Financing Notes and related warrants to purchase 27,365 Holdco Ordinary Shares.
• Noah Klein, Nuvos Vice President of Business Development, and Ari Klein, one of Nuvos employees, are the sons of Laurence Klein, one of Holdcos directors.

Stakeholder Impact

• The company's ability to continue as a going concern is uncertain, which could impact shareholders, employees, customers, and suppliers.
• The company's focus on remote fetal monitoring could improve access to care for expectant mothers, particularly those in rural areas or with high-risk pregnancies.
• The company's INVU platform has the potential to reduce the cost of care for payers and improve outcomes for expectant mothers and unborn babies.

Next Steps

• The company intends to seek clearance to extend its INVU monitoring period and report other measurements.
• The company plans to utilize the data it collects to establish cloud-based decision support systems.
• The company expects to apply data algorithms and other innovative digital tools to conduct AI-powered machine learning and computer-based predictive analytics.

Key Dates

Keywords

INVU platform, fetal monitoring, Nuvo, Holdco, financial results, 20-F, annual report, business combination